| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/13/2004 | US20040091945 Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease |
| 05/13/2004 | US20040091901 Of given amino acid sequence; use in diagnosis and treatment of enzootic pneumonia in swine; kits |
| 05/13/2004 | US20040091894 Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof |
| 05/13/2004 | US20040091890 Life sciences business systems and methods |
| 05/13/2004 | US20040091856 DNA sequences from staphylococcus aureus bacteriophage 44AHJD that encode anti-microbial polypeptides |
| 05/13/2004 | US20040091851 HCV peptide compositions |
| 05/13/2004 | US20040091578 Treating a protein containing disulfide bonds withthioredoxin, nicotinamide adenine dinucleotide phosphate- thioredoxin reductase and NADPH or dithiothreitol reacting the protein with physiological disulfide; administering |
| 05/13/2004 | US20040091503 Lectin compositions and methods for modulating an immune response to an antigen |
| 05/13/2004 | US20040091502 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 05/13/2004 | US20040091501 Immunosuppresor agent derived from morbillivirus |
| 05/13/2004 | US20040091500 Non-naturally occurring mutants from naturally occurring allergens; overall alpha-carbon backbone tertiary structure of the allergens is preserved; use in vaccines; treating allergies; reduced immunoglobulin E (IgE) binding |
| 05/13/2004 | US20040091499 Modified mite allergen and pharmaceutical uses thereof |
| 05/13/2004 | US20040091496 Vaccine |
| 05/13/2004 | US20040091495 Protein |
| 05/13/2004 | US20040091494 P. aeruginosa mucoid exopolysaccharide specific binding peptides |
| 05/13/2004 | US20040091493 Active ingredient such as specified plant extract(s) or calcium compound that does not cause any inflammatory, irritation or intolerance reactions; tissue models for drug screening for drugs against skin disorders; dandruff, acne |
| 05/13/2004 | US20040091492 Use in tumor therapy; vaccine adjuvant to enhance cytotoxic T-cell (CTL) response; fusion proteins incorporate onto the surface of Major Histocompatibility Complex I expressing cells to increase CTL response to antigens on the cells |
| 05/13/2004 | US20040091491 An immune response modifier portion such as a Toll-like receptor or an imidazoquinoline compound paired with an antigenic portion; use of toll-like receptor improves immune response over conventional immune response modifiers |
| 05/13/2004 | US20040091490 Where the antibody is conjugated to a polymer such as polyethylene glycol and contains a succinimide linker, and buffer maintains an acidic pH of 3.5 to 6; storage stability; anti-TNF-alpha antibodies for inflammatory disease treatment |
| 05/13/2004 | US20040091488 Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof |
| 05/13/2004 | US20040091485 Humanised antibodies to the epidermal growth factor receptor |
| 05/13/2004 | US20040091484 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/13/2004 | US20040091481 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 05/13/2004 | US20040091479 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy |
| 05/13/2004 | US20040091477 Immunophilin-binding compound and ginkgolide compound |
| 05/13/2004 | US20040091476 Enhance or suppress T-cell activation and proliferation |
| 05/13/2004 | US20040091464 Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| 05/13/2004 | DE10249594A1 Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV) Immunization against components of the human immunodeficiency virus (HIV) |
| 05/13/2004 | DE10249390A1 Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria Recombinant MVA strains as potential vaccines against P. falciparum malaria |
| 05/13/2004 | CA2505852A1 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 05/13/2004 | CA2505611A1 Activation of hcv-specific cells |
| 05/13/2004 | CA2504178A1 Methods and kits for diagnosing tumorigenicity |
| 05/13/2004 | CA2503946A1 Drying process |
| 05/13/2004 | CA2503763A1 Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 05/13/2004 | CA2485342A1 Humanized antibodies against the venezuelan equine encephalitis virus |
| 05/12/2004 | EP1418235A2 Intracellular domain of the her-2/neu protein for prevention or treatment of maligancies |
| 05/12/2004 | EP1418180A2 Chimeric chains that code for proteins that induce effects directed against viruses |
| 05/12/2004 | EP1417973A2 Vaccine formulation potentiated by the combination of a dna and an antigen |
| 05/12/2004 | EP1417971A2 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 05/12/2004 | EP1417487A2 Epitope testing using hla |
| 05/12/2004 | EP1417353A1 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin |
| 05/12/2004 | EP1417304A2 Method and composition for inhibiting heparanase activity |
| 05/12/2004 | EP1417300A1 Process for the maturation of dentritic cells and a vaccine |
| 05/12/2004 | EP1417236A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 05/12/2004 | EP1417234A2 Recombinant anti-plasmodium falciparum antibodies |
| 05/12/2004 | EP1417232A2 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 05/12/2004 | EP1417229A2 Methods and compounds for the targeting of protein to exosomes |
| 05/12/2004 | EP1417228A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/12/2004 | EP1417227A2 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/12/2004 | EP1417226A1 Derp1 and proderp1 allergen derivatives |
| 05/12/2004 | EP1417224A2 Secreted proteins |
| 05/12/2004 | EP1417221A2 Mimotope of neisseria meningitidis lipooligosaccharide and vaccines containing the same |
| 05/12/2004 | EP1417217A2 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 05/12/2004 | EP1417214A2 Cancer specific oligosaccharide sequences and use thereof |
| 05/12/2004 | EP1416986A2 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 05/12/2004 | EP1416970A2 Conjugate |
| 05/12/2004 | EP1416964A2 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 05/12/2004 | EP1416962A2 Method of improving cognitive function |
| 05/12/2004 | EP1416961A1 Composition and method for the treatment of disease |
| 05/12/2004 | EP1416960A1 Vegfr-1 antibodies to treat breast cancer |
| 05/12/2004 | EP1416959A2 Liposomes prepared from the extractable lipids from a mycobacterium |
| 05/12/2004 | EP1416958A1 Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other |
| 05/12/2004 | EP1416957A2 Treatment of immune disorders and b cell disorders |
| 05/12/2004 | EP1416956A2 Autologous t-cell vaccines materials and method |
| 05/12/2004 | EP1416954A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer |
| 05/12/2004 | EP1416945A1 Improved heteropolymer complexes and methods for their use |
| 05/12/2004 | EP1416932A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 05/12/2004 | EP1416916A1 Chitin microparticles and their medical uses |
| 05/12/2004 | EP1416885A2 Methods and devices for delivery of therapeutic capable agents with variable release profile |
| 05/12/2004 | EP1416884A2 Delivery of therapeutic capable agents |
| 05/12/2004 | EP1416789A1 Propagation of human hepatoblastoma cell in non-human animals |
| 05/12/2004 | EP1151756A4 Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus |
| 05/12/2004 | EP0964700B1 Pharmaceutical preparation and method for treatment and prevention of fibromyalgia and chronic fatigue |
| 05/12/2004 | EP0833911B1 Cdr-grafted anti-tissue factor antibodies and methods of use thereof |
| 05/12/2004 | EP0792156B1 Medicaments for the prevention or treatment of vascular hemorrhaging |
| 05/12/2004 | EP0607425B1 Epstein-barr virus peptides and antibodies against these peptides |
| 05/12/2004 | CN1496369A Modified interferon beta with reduced immunogenicity |
| 05/12/2004 | CN1495262A Non-splicing variant of gp 350/220 |
| 05/12/2004 | CN1494922A Purification method of dermatonecrotoxin and anatoxin produced by Bordetella |
| 05/12/2004 | CN1149288C Novel polypeptide originating in hemophilus paragallinarum and process for producing the same |
| 05/12/2004 | CN1149224C Monoclonal antibody which recognizes the oligosaccharide N-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 05/12/2004 | CN1149012C Medicine kit for concatenated immunodetection of fish diseases |
| 05/11/2004 | US6734286 Interleukin-5 specific recombinant antibodies |
| 05/11/2004 | US6734285 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, inflammation, diabetic retinopathy, rheumatoid arthritis and psoriasis |
| 05/11/2004 | US6734173 HSP DNA vaccines |
| 05/11/2004 | US6734172 Surface receptor antigen vaccines |
| 05/11/2004 | US6734168 Endothelial monocyte activating polypeptide II: a mediator which activates host response |
| 05/11/2004 | US6734013 Genetic engineering |
| 05/11/2004 | US6734003 Phosphodiesterase 10 |
| 05/11/2004 | US6733994 Highly expressible genes |
| 05/11/2004 | US6733989 Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof |
| 05/11/2004 | US6733981 Antibodies to interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 05/11/2004 | US6733973 Diagnostic reagents for human cytomegalovirus and methods of use |
| 05/11/2004 | US6733763 Using antigen; oil in water emulsion |
| 05/11/2004 | US6733760 Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| 05/11/2004 | US6733759 Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals |
| 05/11/2004 | US6733758 Fibrinogen binding protein originating from coagulase-negative staphylococcus |
| 05/11/2004 | US6733754 Adjuvants for use in vaccines |
| 05/11/2004 | US6733743 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 05/11/2004 | CA2302033C Methods and compositions for enhanced wound healing |